Introduction {#sec1_1}
============

The incidence of renal cell carcinoma (RCC) in hemodialysis patient is higher than in non-dialysis patients, reaching 1.5% \[[@B1]\]. However, there is no established treatment for hemodialysis patients with RCC \[[@B2]\]. While some tyrosine kinase inhibitors (TKIs) have been used for metastatic RCC (mRCC) in patients with end-stage kidney disease at a reduced dose, no dose-reduction evidence exists concerning immune-checkpoint inhibitors, such as ipilimumab and nivolumab, so all hemodialysis patients undergo full-dose treatment for mRCC. Regarding nivolumab, two cases have been reported concerning mRCC in patients receiving hemodialysis \[[@B2], [@B3]\].

We herein report a case of the long-term control of dialysis-related RCC using nivolumab.

Case Presentation {#sec1_2}
=================

A 68-year-old man was referred to our hospital for the further examination of a right renal mass in November 2014. He had been received hemodialysis due to end-stage kidney dysfunction induced by chronic glomerulus nephritis since 1996. In February 2015, right nephrectomy was performed. A pathological examination showed clear cell carcinoma combined with papillary RCC in the cystic area, and the surgical margin was negative. During follow-up, a left right tumor was revealed by scheduled computed tomography (CT), so left nephrectomy was performed in July 2015. The pathological diagnosis was metastatic RCC. In October 2015, follow-up CT detected an enlarged right adrenal mass (131.9 mm diameter), so sunitinib (25 mg) was administered. He received sunitinib treatment for 9 courses but discontinued it due to liver metastasis on January 2017. He then received nivolumab as a second-line treatment from March 2017. Nivolumab was administered at a full dose and continued for to 32 courses until August 2018 (Fig. [1](#F1){ref-type="fig"}). The tumor size was controlled as stable disease (SD), but he died on October 2018.

Discussion {#sec1_3}
==========

Since it was first reported by Dunill et al. in 1977, the incidence of RCC has been shown to be higher in dialysis patients than in non-dialysis patients, especially for young men \[[@B4], [@B5]\]. The mean duration from dialysis installation to RCC development is 8 to 10 years, but some patients develop RCC after about 5 years.

For advanced or recurrent mRCC, nivolumab has been used as a second-line treatment in Japan. In 2018, combination therapy between ipilimumab and nivolumab was introduced as a first-line treatment for mRCC. The CheckMate-025 study revealed that nivolumab resulted in an overall survival of 25.0 months, compared to 19.6 months with standard treatment (*p* = 0.002) \[[@B6], [@B7]\]. However, no previous studies have included patients receiving dialysis.

There have been few reports describing TKI or immune-check point inhibitor treatment \[[@B8], [@B9], [@B10]\]. While the ideal dose of TKI for end-stage kidney disease has not been established, in most cases, some degree of dose reduction is applied. For nivolumab treatment, only two cases have been reported \[[@B2], [@B3]\], and all cases - including our own - received nivolumab without dose reduction (Table [1](#T1){ref-type="table"}).

Carlo et al. reported that nivolumab was not affected by the renal function or dialysis, so dose reduction was not necessary \[[@B2]\]. All cases showed efficacy and were able to receive full-dose treatment of nivolumab \[[@B2], [@B3], [@B11]\]. Our patient was able to continue nivolumab treatment for 15 months, and radiographic progression was not detected, although the patient ultimately died 17 months after installation of nivolumab. Pre-nivolumab treatment in our case consisted of only sunitinib, whereas other previous cases used 3 and 6 regimens before nivolumab treatment (Table [1](#T1){ref-type="table"}).

We herein report a fourth case of nivolumab treatment for RCC in a patient receiving hemodialysis.
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Nivolumab treatment in mRCC patients that underwent dialysis

                 Age, years   Gender   Pathology                TNM stage   Prior treatment                                                                                Time from diagnosis to nivolumab
  -------------- ------------ -------- ------------------------ ----------- ---------------------------------------------------------------------------------------------- ----------------------------------
  Carloet al.    77           Male     Clear cell               pT2aNxM0    Partial nephrectomy, radical nephrectomy, pazopanib, everolimus, sorafenib                     2 years, 10 months
  Tabei et al.   49           Male     Clear cell               pT1bNxM1    Radical nephrectomy, Interferon alpha, sorafenib, everolimus, sunitinib, axitinib, pazopanib   8 years, 11 months
  Current case   68           Male     Clear cell + papillary   pT1aN1M0    Radical nephrectomy, sunitinib                                                                 2 years, 4 months
